Drug Eluting Balloon Angioplasty Versus Nitinol Stent Implantation in the Superficial Femoral Artery
Launched by INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA · Aug 7, 2014
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients over 18 years with critical lower limb ischemia,
- • Ruhtherford 3 or higher,
- • with angiographic documentation of greater than 70% or occlusion in the superficial femoral artery,
- • with a maximum extension of 10 cm stenosis.
- • The popliteal artery and at least one leg artery must be patent.
- Exclusion Criteria:
- • Pregnancy,
- • thrombophilia,
- • coagulation disorders,
- • presence of active or recent bleeding,
- • severe allergy to iodinated contrast,
- • renal or hepatic disease,
- • acute limb ischemia,
- • prior surgical bypass or angioplasty (with or without stent) on the target artery,
- • obstructive disease (stenosis\> 50%) of the aortoiliac segment ipsilateral to the target (if the aortoiliac is pre-treated, the patient may be included)
About Instituto Dante Pazzanese De Cardiologia
Instituto Dante Pazzanese de Cardiologia is a leading clinical research institution based in Brazil, dedicated to advancing cardiovascular medicine through innovative research and clinical trials. Renowned for its commitment to improving patient outcomes, the institute specializes in a wide array of cardiovascular conditions and interventions. With a multidisciplinary team of experts, state-of-the-art facilities, and a robust network of collaboration, Instituto Dante Pazzanese de Cardiologia plays a pivotal role in contributing to the scientific community and enhancing the understanding of heart diseases, ultimately striving to translate research findings into effective clinical practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sao Paulo, , Brazil
Patients applied
Trial Officials
BRUNO L ALMEIDA, MD
Principal Investigator
Instituto Dante Pazzanese de Cardiologia
FABIO H ROSSI, MD, PHD
Study Director
Instituto Dante Pazzanese de Cardiologia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials